A wrap of the day’s activity on the Australian stock market.
Trading profits in US energy markets in particular have allowed Macquarie Group to define a solid profit increase for FY14, but is there anymore share price upside to be had?
The US FDA has approved Cochlear’s Nucleus Hybrid L24. It’s a welcome development but brokers remain focused on the challenges ahead.
A wrap of the day’s activity on the Australian stock market.
Metcash has revealed its eagerly-awaited strategy to put the business on a better footing and return to growth.
FNArena provides a weekly update of Australian listed corporate bond issues, current pricing and yield data.
Weekly update on recommendation, target price, and earnings forecast changes.
A wrap of the day’s activity on the Australian stock market.
A wrap of the day’s activity on the Australian stock market.
FNArena’s weekly update on short positions in the Australian share market.